NCT02000804View on ClinicalTrials.gov

Darapladib China PK

PHASE1CompletedINTERVENTIONAL

Enrollment

24

Participants

Timeline

Start Date

October 23, 2013

Primary Completion Date

January 4, 2014

Study Completion Date

January 4, 2014

Conditions

Atherosclerosis

Interventions

DRUG

darapladib 160mg

drug

Trial Locations (1)

200030

GSK Investigational Site, Shanghai

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY